SAKAR HEALTHCARE Q2 : CONS NET PROFIT UP 149% AT RS 11.31 CR (YOY). STRONG (ON 1ST LOOK)

Revenue up ~52% at ₹87.42 Cr (YOY); H1 revenue ₹160.39 Cr, up 45% (YOY). Ebitda up 114% at ₹24.35 Cr (YOY); margins 28% v 20% (YOY). Gross profit up 53% at ₹41.68 Cr (YOY); margins 48% v 47% (YOY); H1 PAT ₹21.59 Cr, up 134% (YOY). Commercial supplies begun from API-integrated, EU GMP-approved oncology FDF site; 69 oncology product contracts executed, 45 commercial discussions underway. 22 MAs granted with 191 dossiers submitted to regulators and 36 EU MA applications completed.

Sakar Healthcare Limited

Open attachment

← Back to feed